Company intelligence / Profile preview

Shiner Pharm Corp.

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Shiner Pharm Corp. develops and commercializes innovative hospital specialty pharmaceutical products, focusing on medicines that significantly improve patient health and reduce disease burden. Their current pipeline includes at least two drug candidates targeting gastrointestinal diseases, both in early clinical or preclinical stages ("pending"). The company was founded in 2011 after spinning off from an associated entity to strengthen its R&D capabilities and pursue a global presence[2][5].

Therapeutic areas: Gastroenterology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

S-7

Preclinical

Partnerships

Exclusive supply/distribution agreement with a Dutch company for Class I dermatology medical products[1]

Beyond the preview

Go deeper on Shiner Pharm Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shiner Pharm Corp..

Explore the full profile